awards PsychoGenics additional funds to continue the Scout Program

June 22, 2016

Cincinnati, OH – It is with great excitement that announces that it has funded PsychoGenics for a third year as it continues its Scout Program, a pre-clinical trial program in a mouse model of Rett syndrome.  This program was implemented to identify potential candidate drugs to treat Rett syndrome.  To date the program has tested 15 compounds and three of the compounds that have proven to show improvements in the mouse model are moving forward to clinical trials.’s Chief Science Officer, Steven Kaminsky, Ph.D., has stated “The continued funding of the Scout Program is exciting because this program provides standardized testing in a Rett syndrome animal model with all compounds examined under blinded and randomized conditions.  Having a platform that is identical for all compounds tested allows us the opportunity to identify the treatment(s) with the most potential to be effective and to then work with the pharmaceutical industry to move forward toward clinical trials in Rett syndrome.”

Currently and PsychoGenics have 9 compounds in the pipeline to be tested over the next year.  The compounds to be tested in the coming year examine their ability to correct a number of biochemical pathways that have been demonstrated to be aberrant in Rett syndrome.

About the Scout Program

In 2011, a workshop focused on the state of the art in animal studies of Rett syndrome was convened by the National Institute of Neurological Disorders and Stroke (NINDS), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and Rett Syndrome Research Trust. The participants recommended important guidelines that the community of Rett researchers can implement to ensure more standardized study design and transparent reporting.

In response to the workshop, developed the Scout Program to serve the many entities that are performing preclinical research with the ultimate goal to accelerate research towards more human clinical trials.’s strategy with this program is to independently test selected drugs using the guidelines set by the NINDS/NICHD workshop to provide the complementary high quality data required to move promising compounds along the drug development pipeline toward the clinic. Working together with academic labs and the pharmaceutical industry will ensure that rigorous and high-quality preclinical trial designs are employed to generate the robust and reliable preclinical data required to shorten the time to effective treatments.

About PsychoGenics

PsychoGenics is a leading provider of preclinical CNS services.  The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. Complementing its extensive capabilities, the company has a variety of mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Rett Syndrome, and  muscle disorders. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube®, and PhenoCube® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and has resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

About accelerates full spectrum research towards curing Rett syndrome (RTT) and empowers families with knowledge and connectivity. As the world’s leading comprehensive private funder of RTT research, we have invested more than $38 million in peer-reviewed research grants and programs to date. We are a 501(c)3 organization, earning Charity Navigator’s most prestigious 4-star rating. Visit to learn more, or call (800) 818-7388.

About Rett Syndrome (RTT)

Rett syndrome is a rare non-inherited genetic postnatal neurological disorder that occurs almost exclusively in girls and leads to lifelong impairments, affecting nearly every aspect of the child’s life: their ability to speak, walk, and eat is effected, seizures develop and scoliosis occurs, and many develop irregular breathing patterns. Those diagnosed with Rett syndrome, about 1 in 10,000 girls, require maximum assistance with basic daily activities. The hallmark sign of Rett syndrome is near constant repetitive hand movements. Cognitive assessment in children with Rett syndrome is complicated, but they understand far more than they can communicate, evidenced by their bright and attentive eyes, and their ability to express a wide spectrum of moods and emotions.